---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-003537"
form_type: "8-K/A"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:56:09.850586+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options

## Summary
- Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.
- Nolan receives option for 1,106,131 shares; 25% vests Dec 16, 2023, remainder monthly over 36 months.
- Sukumar Nagendran appointed President & Head of R&D; base $565K, bonus target 50%, option for 790,093 shares with same vesting.
- Severance: Nolan gets 18 months salary + 150% target bonus; Nagendran 15 months + 100% target bonus upon qualifying termination.

## SEC filing metadata
- accession: 0001193125-23-003537
- form_type: 8-K/A
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/d410825d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-003537
- JSON: https://secwatch.observer/filing/0001193125-23-003537.json
- Plain text: https://secwatch.observer/filing/0001193125-23-003537.txt

## Key facts
- Executive change
  Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: President and Head of Research and Development
  source text: the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm
- Executive change
  Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.